Expanding use of recombinant hTSH

L. Fugazzola

Research output: Contribution to journalArticle

Abstract

The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen®, Genzyme Corp., Cambridge, MA, USA) are well established as an alternative stimulation procedure to thyroid hormone withdrawal in the follow-up of thyroid cancer patients. rhTSH has the advantage to avoid both hypothyroidism, with a major impact on the quality of life, and the side effects on tumor growth related to the long-lasting TSH increase. More recently, alternative uses have been proposed, including treatment of nodular goiter, TSH stimulation to enhance PET scanning and chemotherapy treatment, and differential diagnosis of congenital hypothyroidism. In benign thyroid diseases, rhTSH administration increases thyroid uptake resulting in a more homogeneous distribution of the tracer, and allows to reduce the dose of 131I maintaining the same effects on thyroid shrinkage. Moreover, rTSH stimulation improves the detectability of occult thyroid metastases with FDG-PET, and promising results have been obtained in the response rate of poorly differentiated thyroid cancer submitted to chemotherapy after rhTSH stimulation. Finally, rhTSH testing has been proved to be safe and to lead, in association with ultrasound, to the differential diagnosis of congenital hypothyroidism during L-thyroxine, allowing the appropriate clinical/genetic management of the disease and thus representing a valuable alternative to L-thyroxine withdrawal.

Original languageEnglish
Pages (from-to)220-223
Number of pages4
JournalAnnales d'Endocrinologie
Volume68
Issue number4
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Thyrotropin Alfa
Congenital Hypothyroidism
Thyroid Gland
Thyroxine
Thyroid Neoplasms
Differential Diagnosis
Nodular Goiter
Drug Therapy
Inborn Genetic Diseases
Thyroid Diseases
Thyrotropin
Hypothyroidism
Thyroid Hormones
Quality of Life
Neoplasm Metastasis
Therapeutics
Growth

Keywords

  • Congenital hypothyroidism
  • Nodular goiter
  • Radioiodine uptake
  • Recombinant human TSH

ASJC Scopus subject areas

  • Endocrinology

Cite this

Expanding use of recombinant hTSH. / Fugazzola, L.

In: Annales d'Endocrinologie, Vol. 68, No. 4, 09.2007, p. 220-223.

Research output: Contribution to journalArticle

Fugazzola, L. / Expanding use of recombinant hTSH. In: Annales d'Endocrinologie. 2007 ; Vol. 68, No. 4. pp. 220-223.
@article{f3fe02325e124992ad71a945d075766e,
title = "Expanding use of recombinant hTSH",
abstract = "The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen{\circledR}, Genzyme Corp., Cambridge, MA, USA) are well established as an alternative stimulation procedure to thyroid hormone withdrawal in the follow-up of thyroid cancer patients. rhTSH has the advantage to avoid both hypothyroidism, with a major impact on the quality of life, and the side effects on tumor growth related to the long-lasting TSH increase. More recently, alternative uses have been proposed, including treatment of nodular goiter, TSH stimulation to enhance PET scanning and chemotherapy treatment, and differential diagnosis of congenital hypothyroidism. In benign thyroid diseases, rhTSH administration increases thyroid uptake resulting in a more homogeneous distribution of the tracer, and allows to reduce the dose of 131I maintaining the same effects on thyroid shrinkage. Moreover, rTSH stimulation improves the detectability of occult thyroid metastases with FDG-PET, and promising results have been obtained in the response rate of poorly differentiated thyroid cancer submitted to chemotherapy after rhTSH stimulation. Finally, rhTSH testing has been proved to be safe and to lead, in association with ultrasound, to the differential diagnosis of congenital hypothyroidism during L-thyroxine, allowing the appropriate clinical/genetic management of the disease and thus representing a valuable alternative to L-thyroxine withdrawal.",
keywords = "Congenital hypothyroidism, Nodular goiter, Radioiodine uptake, Recombinant human TSH",
author = "L. Fugazzola",
year = "2007",
month = "9",
doi = "10.1016/j.ando.2007.06.010",
language = "English",
volume = "68",
pages = "220--223",
journal = "Annales d'Endocrinologie",
issn = "0003-4266",
publisher = "Elsevier Masson",
number = "4",

}

TY - JOUR

T1 - Expanding use of recombinant hTSH

AU - Fugazzola, L.

PY - 2007/9

Y1 - 2007/9

N2 - The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen®, Genzyme Corp., Cambridge, MA, USA) are well established as an alternative stimulation procedure to thyroid hormone withdrawal in the follow-up of thyroid cancer patients. rhTSH has the advantage to avoid both hypothyroidism, with a major impact on the quality of life, and the side effects on tumor growth related to the long-lasting TSH increase. More recently, alternative uses have been proposed, including treatment of nodular goiter, TSH stimulation to enhance PET scanning and chemotherapy treatment, and differential diagnosis of congenital hypothyroidism. In benign thyroid diseases, rhTSH administration increases thyroid uptake resulting in a more homogeneous distribution of the tracer, and allows to reduce the dose of 131I maintaining the same effects on thyroid shrinkage. Moreover, rTSH stimulation improves the detectability of occult thyroid metastases with FDG-PET, and promising results have been obtained in the response rate of poorly differentiated thyroid cancer submitted to chemotherapy after rhTSH stimulation. Finally, rhTSH testing has been proved to be safe and to lead, in association with ultrasound, to the differential diagnosis of congenital hypothyroidism during L-thyroxine, allowing the appropriate clinical/genetic management of the disease and thus representing a valuable alternative to L-thyroxine withdrawal.

AB - The clinical benefits of recombinant human thyroid-stimulating hormone (rhTSH; Thyrogen®, Genzyme Corp., Cambridge, MA, USA) are well established as an alternative stimulation procedure to thyroid hormone withdrawal in the follow-up of thyroid cancer patients. rhTSH has the advantage to avoid both hypothyroidism, with a major impact on the quality of life, and the side effects on tumor growth related to the long-lasting TSH increase. More recently, alternative uses have been proposed, including treatment of nodular goiter, TSH stimulation to enhance PET scanning and chemotherapy treatment, and differential diagnosis of congenital hypothyroidism. In benign thyroid diseases, rhTSH administration increases thyroid uptake resulting in a more homogeneous distribution of the tracer, and allows to reduce the dose of 131I maintaining the same effects on thyroid shrinkage. Moreover, rTSH stimulation improves the detectability of occult thyroid metastases with FDG-PET, and promising results have been obtained in the response rate of poorly differentiated thyroid cancer submitted to chemotherapy after rhTSH stimulation. Finally, rhTSH testing has been proved to be safe and to lead, in association with ultrasound, to the differential diagnosis of congenital hypothyroidism during L-thyroxine, allowing the appropriate clinical/genetic management of the disease and thus representing a valuable alternative to L-thyroxine withdrawal.

KW - Congenital hypothyroidism

KW - Nodular goiter

KW - Radioiodine uptake

KW - Recombinant human TSH

UR - http://www.scopus.com/inward/record.url?scp=34548386673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548386673&partnerID=8YFLogxK

U2 - 10.1016/j.ando.2007.06.010

DO - 10.1016/j.ando.2007.06.010

M3 - Article

C2 - 17689475

AN - SCOPUS:34548386673

VL - 68

SP - 220

EP - 223

JO - Annales d'Endocrinologie

JF - Annales d'Endocrinologie

SN - 0003-4266

IS - 4

ER -